Name | Garazhno-stroitel'nyy kooperativ "ORBITA-5" |
|---|
INN | 7729208120 |
|---|
KPP | 772901001 |
|---|
OGRN | 1037739004511 |
|---|
OKPO | 17768550 |
|---|
Address | 119361, gorod Moskva, ul. Lobachevskogo, d. D. 114, of. OFIS 18A |
|---|
Phone | 433-20-88 |
|---|
|
| OKVED code | Type | Name of activity type |
|---|
| 63.21.24 | Core activity | Garages and car stations operation |
Registration date | 04.01.2003 |
|---|
Registering department | Gosudarstvennoe uchrezhdenie Moskovskaya registratsionnaya palata |
|---|
|
GSK "ORBITA-5" (Moscow; INN 7729208120) was registered on 4 Jan 2003. Type of ownership of GSK "ORBITA-5" - Comsumer cooperatives. Form of ownership of GSK "ORBITA-5" - Private property. Principal activities of GSK "ORBITA-5": garages and car stations operation (63.21.24). |
Economic indicators2023
Net loss (RAS) of GSK ORBITA-5 dropped over 2023 8.88 times to 16.58 million RUB from 147.22 million RUB KAgent.Entities.Balance, the company informed. 2022
Net loss (RAS) of GSK ORBITA-5 increased 10.46 times to 147.22 million RUB from 14.08 million RUB over 2021, the company informed. 2021
Net loss (RAS) of GSK ORBITA-5 dropped over 2021 49.28 times to 14.08 million RUB from 693.92 million RUB KAgent.Entities.Balance, the company informed. 2020
Net loss (RAS) of GSK ORBITA-5 increased 10.34 times to 693.92 million RUB from 67.08 million RUB over 2019, the company informed. Revenue decreased in the accounting period ? times to 0.00 thousand RUB from 13.24 million RUB in 2019; cost of goods sold decreased 2.18 times to 320.00 thousand RUB from 699.00 thousand RUB; sales loss grew by 29.80% to 76.02 million RUB from 58.57 million RUB. 2019
Net loss (RAS) of GSK ORBITA-5 dropped over 2019 3.68 times to 57.51 million RUB from 211.63 million RUB KAgent.Entities.Balance, the company informed. Revenue decreased in the accounting period by 41.68% to 13.24 million RUB from 22.70 million RUB in 2018; cost of goods sold grew by 9.05% to 699.00 thousand RUB from 641.00 thousand RUB; sales loss grew 3.29 times to 58.57 million RUB from 17.81 million RUB. 2017
Net loss (RAS) of GSK ORBITA-5 dropped over 2017 by 13.40% to 247.66 million RUB from 285.99 million RUB KAgent.Entities.Balance, the company informed. Revenue increased in the accounting period by 10.94% to 52.18 million RUB from 47.03 million RUB over 2016; sales loss made up 2.44 million RUB compared to sales profit of 12.83 million RUB. 2016
Net loss (RAS) of GSK ORBITA-5 increased 3.21 times to 285.99 million RUB from 89.08 million RUB over 2015, the company informed. Revenue decreased in the accounting period by 10.31% to 47.03 million RUB from 52.44 million RUB in 2015; sales profit fell by 30.25% to 12.83 million RUB from 18.40 million RUB. 2014
Net profit (RAS) of GSK ORBITA-5 made up 9.27 million RUB over 2014 compared to net loss of 43.80 million RUB over 2013, the company informed. Revenue increased in the accounting period by 2.76% to 65.29 million RUB from 63.54 million RUB over 2013; sales profit made up 30.51 million RUB compared to sales loss of 22.87 million RUB. 2013
Net loss (RAS) of GSK ORBITA-5 increased by 4.71% to 43.80 million RUB from 41.83 million RUB over 2012, the company informed. Revenue increased in the accounting period by 2.31% to 63.54 million RUB from 62.10 million RUB over 2012; sales loss made up 22.87 million RUB compared to sales profit of 51.81 million RUB. 2012
Net loss (RA) of GSK ORBITA-5 made up 41.83 million RUB over 2012 compared to net profit of 9.00 thousand RUB over 2011, the company informed. Cost of goods sold decreased Infinity times to 0.00 thousand RUB from 592.00 thousand RUB; sales profit went up 4,709.82 times to 51.81 million RUB from 11.00 thousand RUB.
unlimited access to database "Kontragent" download any information within 24 hours
Companies in the region
|